SynAct Pharma’s recently acquired affiliate TXP Pharma was granted a patent in Canada related to “Alpha- and gamma-MSH analogues”.
In addition, TXP’s patent application in another patent family relating to ”Exendin-4-analogues” has entered national phase in significant countries and regions worldwide.
TXP Pharma operates as a fully owned subsidiary and was recently acquired to strengthen SynAct Pharma’s position in autoimmune diseases.
Alpha- and gamma-MSH analogues
Alpha- and gamma-MSH analogues are peptides based on modifications of endogenous ligands to the melanocortin receptors, that plays a pivotal role in resolution of inflammation. TXP has applied its Branched Amino Acid Probes (BAP) to these peptides, and the new patent in Canada belongs to a family, where patents have been issued in several countries and regions, including Europe, Japan, and USA.
The Exendin-4-analogues are currently not a strategic focus point for SynAct Pharma, but it demonstrates the versatility of the BAP-technology that is a key asset in TXP Pharma. The BAP-modification of peptides has a large potential in a variety of indications and for the development of novel drugs, including the melanocortin analogue TXP-11, the leading peptide drug candidate, and other melanocortin analogues developed by TXP Pharma.
The patent application will be evaluated by the individual authorities in a process that may vary from country to country, and will, if successful, result in granting of patents as a next step.